MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...
SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a US comparative effectiveness study of two maintenance treatment options for patients with a history of chronic obstructive pulmonary disease (COPD) ...
The victory marks the fourth Symbicort patent deemed invalid or not infringed in court, Viatris and Kindeva pointed out. (Viatris) In the courtroom fracas over the patents on AstraZeneca’s ...
AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers ...
AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
Add Yahoo as a preferred source to see more of our stories on Google. Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results